StreetInsider.com News Articles

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

TORONTO and DALLAS, Nov. 8, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK)(OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its third quarter 2024 financial and operating results after market close on Thursday, November 14, 2024. Following the announcement, Perimeter management will host a webcast and conference call to

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Medical Imaging AI to Report Third Quarter 2024 Financial Results and Host Conference Call on November 14, 2024

Fri, 08 Nov 2024 08:00:00 -0400

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent

Perimeter Announces Completion of Patient Enrollment in Pivotal Clinical Trial Evaluating OCT B-Series with ImgAssist AI in Breast-Conserving Surgeries

Tue, 01 Oct 2024 16:15:00 -0400

– Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS –

– Recent study¹ published in the Annals of Surgical Oncology revealed reoperation rates of 21.1% among commercially insured women and 14.9% among the Medicare cohort –

– Primary endpoint results from OCT B-Series pivotal trial expected in Q4-2024; could support submission to FDA in 2025 –

– First-ever marketing clearance for specific use in breast tissue, breast cancer, and margin evaluation, if obtained, would represent